Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Accumulated Expenses: 2022-2025

Historic Accumulated Expenses for Legend Biotech (LEGN) over the last 2 years, with Mar 2025 value amounting to $24.1 million.

  • Legend Biotech's Accumulated Expenses fell 72.73% to $24.1 million in Q1 2025 from the same period last year, while for Mar 2025 it was $24.1 million, marking a year-over-year decrease of 72.73%. This contributed to the annual value of $16.3 million for FY2024, which is 77.12% down from last year.
  • Legend Biotech's Accumulated Expenses amounted to $24.1 million in Q1 2025, which was up 47.37% from $16.3 million recorded in Q4 2024.
  • In the past 5 years, Legend Biotech's Accumulated Expenses ranged from a high of $127.4 million in Q4 2022 and a low of $16.3 million during Q4 2024.
  • In the last 3 years, Legend Biotech's Accumulated Expenses had a median value of $89.0 million in 2023 and averaged $75.5 million.
  • Examining YoY changes over the last 5 years, Legend Biotech's Accumulated Expenses showed a top increase of 11.45% in 2024 and a maximum decrease of 77.12% in 2024.
  • Legend Biotech's Accumulated Expenses (Quarterly) stood at $127.4 million in 2022, then plummeted by 43.90% to $71.5 million in 2023, then tumbled by 77.12% to $16.3 million in 2024, then tumbled by 72.73% to $24.1 million in 2025.
  • Its last three reported values are $24.1 million in Q1 2025, $16.3 million for Q4 2024, and $99.8 million during Q3 2024.